Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 22 December 2016 Biocartis and Amgen sign a RAS Biomarker Testing Collaboration in Europe Inside information Regulated information 15 December 2016 CE-marking Idylla™ NRAS-BRAF Mutation Test completes offering of metastatic colorectal cancer tests for clinical use on Idylla™ platform Non-regulated information 14 December 2016 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 12 December 2016 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 7 December 2016 Biocartis launches second liquid biopsy assay Assay co-developed with Merck for detection of KRAS mutations, operating directly on 1 ml blood plasma Non-regulated information 28 November 2016 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 21 November 2016 Disclosure of Outstanding Voting Securities Regulated information 17 November 2016 Thermo Fisher Scientific to Distribute Biocartis’ Idylla™ Automated Molecular Diagnostics Testing Platform in U.S. Inside information Regulated information 17 November 2016 Biocartis Q3 2016 Business Update Regulated information 31 October 2016 Biocartis receives EUR 1.4m grant to support development of its rapid NGS Prep Panels Non-regulated information Pagination First page « First Previous page ‹‹ … Page 24 Page 25 Page 26 Page 27 Current page 28 Page 29 Page 30 Page 31 Page 32 Next page ›› Last page Last »